New Agents in the Treatment for Malignancies of the Salivary and Thyroid Glands

Overview

Journal Hematol Oncol Clin North Am

Specialties Hematology
Oncology

Date 2008 Nov 18

PMID 19010274

Citations 3

Authors

Ranee Mehra

Roger B Cohen

Affiliations

Soon will be listed here.

Abstract

The treatment of relatively rare malignancies, such as those of the salivary glands and iodine refractory thyroid cancer, has been invigorated by the development of novel molecular targeting agents. Accrual to clinical trials for these disease sites continues to be limited by their relatively low incidence. Nonetheless, multicenter collaborations have contributed greatly to the development of a number of emerging systemic therapies. This article briefly summarizes the epidemiology and pathogenesis of salivary gland and thyroid cancer, and then describes some of the new drugs under evaluation for these malignancies.

Citing Articles

The Role of Oral Organs in Local Immunity with Elements of Morphology of Lingual Glands.

Olsufieva A, Vasyanina K, Zotkin D, Klyueva L, Olsufiev S, Chizh R Bull Exp Biol Med. 2021; 172(2):158-163.

PMID: 34855089 DOI: 10.1007/s10517-021-05355-5.

Pediatric Pleomorphic Adenoma of the Parotid: Case Report, Review of Literature and Novel Therapeutic Targets.

Gulab Meshram G, Kaur N, Hura K Children (Basel). 2018; 5(9).

PMID: 30231590 PMC: 6162389. DOI: 10.3390/children5090127.

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

Brose M, Cabanillas M, Cohen E, Wirth L, Riehl T, Yue H Lancet Oncol. 2016; 17(9):1272-82.

PMID: 27460442 PMC: 5532535. DOI: 10.1016/S1470-2045(16)30166-8.

References

Klein M, Picard E, Vignaud J, Marie B, Bresler L, Toussaint B . Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol. 1999; 161(1):41-9. DOI: 10.1677/joe.0.1610041. View

Marsh D, Learoyd D, Andrew S, Krishnan L, Pojer R, Richardson A . Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf). 1996; 44(3):249-57. DOI: 10.1046/j.1365-2265.1996.681503.x. View

Licitra L, Marchini S, Spinazze S, Rossi A, Rocca A, Grandi C . Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer. 1991; 68(9):1874-7. DOI: 10.1002/1097-0142(19911101)68:9<1874::aid-cncr2820680904>3.0.co;2-s. View

Sun E, Curtis R, Melbye M, Goedert J . Salivary gland cancer in the United States. Cancer Epidemiol Biomarkers Prev. 1999; 8(12):1095-100. View

Mulligan L, Eng C, Healey C, Clayton D, Kwok J, Gardner E . Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet. 1994; 6(1):70-4. DOI: 10.1038/ng0194-70. View

Kim K, Kim Y, Kim H, Chae Y, Yoem B, Kim I . The detection of Epstein-Barr virus in the lesions of salivary glands. Pathol Res Pract. 1999; 195(6):407-12. DOI: 10.1016/S0344-0338(99)80014-4. View

Pennell N, Daniels G, Haddad R, Ross D, Evans T, Wirth L . A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2007; 18(3):317-23. DOI: 10.1089/thy.2007.0120. View

Airoldi M, Fornari G, Pedani F, Marchionatti S, Gabriele P, Succo G . Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res. 2001; 20(5C):3781-3. View

Nikiforova M, Kimura E, Gandhi M, Biddinger P, Knauf J, Basolo F . BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003; 88(11):5399-404. DOI: 10.1210/jc.2003-030838. View

10.

McIver B, Grebe S, Eberhardt N . The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Curr Drug Targets Immune Endocr Metabol Disord. 2004; 4(3):221-34. DOI: 10.2174/1568008043339802. View

11.

Tallini G, Asa S . RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol. 2001; 8(6):345-54. DOI: 10.1097/00125480-200111000-00005. View

12.

Karga H, Lee J, VICKERY JR A, Thor A, Gaz R, Jameson J . Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab. 1991; 73(4):832-6. DOI: 10.1210/jcem-73-4-832. View

13.

Santoro M, Melillo R, Carlomagno F, Fusco A, Vecchio G . Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci. 2002; 963:116-21. DOI: 10.1111/j.1749-6632.2002.tb04102.x. View

14.

Seethala R, Barnes E, Hunt J . Epithelial-myoepithelial carcinoma: a review of the clinicopathologic spectrum and immunophenotypic characteristics in 61 tumors of the salivary glands and upper aerodigestive tract. Am J Surg Pathol. 2007; 31(1):44-57. DOI: 10.1097/01.pas.0000213314.74423.d8. View

15.

Lequerica-Fernandez P, Astudillo A, de Vicente J . Expression of vascular endothelial growth factor in salivary gland carcinomas correlates with lymph node metastasis. Anticancer Res. 2007; 27(5B):3661-6. View

16.

Gottlieb J, HILL Jr C, IBANEZ M, CLARK R . Chemotherapy of thyroid cancer. An evaluation of experience with 37 patients. Cancer. 1972; 30(3):848-53. DOI: 10.1002/1097-0142(197209)30:3<848::aid-cncr2820300336>3.0.co;2-2. View

17.

Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V . BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer. 2008; 15(2):511-20. DOI: 10.1677/ERC-07-0130. View

18.

Gottlieb J, HILL Jr C . Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med. 1974; 290(4):193-7. DOI: 10.1056/NEJM197401242900404. View

19.

Laurie S, Licitra L . Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 2006; 24(17):2673-8. DOI: 10.1200/JCO.2005.05.3025. View

20.

Matuszczyk A, Petersenn S, Bockisch A, Gorges R, Sheu S, Veit P . Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res. 2008; 40(3):210-3. DOI: 10.1055/s-2008-1046781. View